HIPAA vs EU MDR: Navigating Healthcare Compliance Across Borders

Healthcare organisations that operate across the United States and the European Union face a compliance challenge that few other industries encounter at the same scale. Two of the most significant regulatory frameworks — HIPAA in the US and the EU Medical Device Regulation (MDR) — govern different aspects of healthcare operations with different philosophies, different structures, and different enforcement mechanisms. Yet for companies that manufacture medical devices, develop health technology, or provide healthcare services internationally, both frameworks apply simultaneously.

Understanding where HIPAA and EU MDR overlap, where they diverge, and where the gaps between them create risk is essential for any organisation navigating cross-border healthcare compliance.

What each framework governs

Before comparing obligations, it is important to understand that HIPAA and EU MDR regulate different things — but their requirements frequently intersect in practice.

HIPAA (the Health Insurance Portability and Accountability Act) is fundamentally a data protection and privacy framework. Its core concern is the protection of Protected Health Information (PHI) — any individually identifiable health information created, received, maintained, or transmitted by a covered entity or business associate. HIPAA’s three main rules — the Privacy Rule, the Security Rule, and the Breach Notification Rule — establish how PHI must be handled, secured, and reported when compromised.

EU MDR (Regulation 2017/745) is a product safety and market access framework. Its core concern is ensuring that medical devices placed on the European market are safe and perform as intended. EU MDR governs the entire lifecycle of a medical device — design, manufacture, clinical evaluation, post-market surveillance, and vigilance reporting.

The intersection occurs wherever medical devices handle health data. A connected medical device, a software-as-a-medical-device (SaMD) product, or a health information system that qualifies as a medical device under EU MDR must comply with both frameworks when it processes patient data across US and EU jurisdictions.

Where the requirements overlap

Despite their different scopes, HIPAA and EU MDR share several areas of overlapping concern.

Risk management is central to both frameworks, though the focus differs. HIPAA’s Security Rule requires covered entities to conduct a risk analysis to identify threats and vulnerabilities to PHI. EU MDR requires manufacturers to implement a comprehensive risk management system covering the entire device lifecycle, typically following ISO 14971. Both demand documented risk assessments, but HIPAA focuses on data security risks while EU MDR focuses on device safety risks. For a connected medical device, both risk domains apply — and they frequently interact.

Documentation and record keeping obligations are extensive under both frameworks:

• HIPAA requires documentation of policies, procedures, risk analyses, training records, and incident response plans. Retention periods are typically six years.
• EU MDR requires comprehensive technical documentation including design and manufacturing information, clinical evaluation reports, risk management files, and post-market surveillance records. Retention is at least 10 years (15 years for implantable devices).

Incident reporting is mandatory under both frameworks, though the triggers, timelines, and recipients differ significantly:

• HIPAA’s Breach Notification Rule requires notification to affected individuals, HHS, and in some cases the media, within 60 days of discovering a breach affecting PHI.
• EU MDR’s vigilance requirements mandate reporting serious incidents to the relevant competent authority. Timelines vary by severity — from 2 days for imminent public health threats to 15 days for other serious incidents.

Quality management systems are required by both frameworks in different forms. HIPAA requires administrative, physical, and technical safeguards — effectively a quality system for data protection. EU MDR requires a full quality management system covering design, production, and post-market activities. Organisations subject to both often align these through frameworks like ISO 13485 (for devices) and ISO 27001 (for information security), but the mapping between HIPAA’s specific requirements and the QMS expected by EU MDR is not one-to-one.

Where the frameworks diverge

The differences between HIPAA and EU MDR are substantial and create the compliance complexity that cross-border organisations must manage.

Scope of “data” obligations: HIPAA is prescriptive about how PHI is handled — access controls, encryption standards, audit controls, transmission security. EU MDR addresses data primarily through the lens of device safety and performance — data integrity, cybersecurity as it affects device function, and privacy by design. The GDPR (which applies alongside EU MDR for any device processing personal data in the EU) adds a third layer of data protection obligations that differ from HIPAA in fundamental ways, including lawful basis for processing, data minimisation, and data subject rights.

Pre-market requirements: EU MDR imposes rigorous pre-market conformity assessment requirements, including clinical evaluation, notified body review (for higher-risk classes), and CE marking. HIPAA has no pre-market requirements — its obligations attach once PHI is being handled. This means a device entering the EU market faces a far more structured pre-market process than the same device entering the US market from a data compliance perspective (though FDA pre-market requirements exist separately).

Post-market obligations: Both frameworks require ongoing monitoring, but the scope differs. EU MDR mandates a comprehensive post-market surveillance system, periodic safety update reports (PSURs), and active participation in vigilance reporting. HIPAA’s ongoing obligations focus on maintaining security safeguards, conducting periodic risk analyses, and responding to breaches. EU MDR’s post-market requirements are generally more prescriptive and resource-intensive.

Enforcement philosophy: HIPAA enforcement is conducted by the HHS Office for Civil Rights (OCR) and can result in civil monetary penalties, corrective action plans, and in extreme cases criminal prosecution. Penalties are tiered based on the level of negligence. EU MDR enforcement operates through competent authorities in each member state and through notified bodies. Non-compliance can result in market withdrawal, suspension of CE certificates, and financial penalties. The EU’s enforcement is fundamentally tied to market access — a firm that cannot demonstrate compliance loses the right to sell in the EU market.

Common gaps in cross-border compliance

Organisations that must comply with both frameworks frequently encounter gaps in the following areas.

Cybersecurity requirements are not aligned. HIPAA’s Security Rule specifies technical safeguards including access controls, audit controls, integrity controls, and transmission security. EU MDR’s cybersecurity expectations (reinforced by MDCG guidance documents) focus on cybersecurity as a device safety issue — secure design, vulnerability management, and cybersecurity risk management throughout the device lifecycle. An organisation can satisfy HIPAA’s technical safeguards while falling short of EU MDR’s cybersecurity expectations, and vice versa. The gap is in the overlap: where data security and device safety intersect, neither framework alone provides complete coverage.

Clinical evidence and data protection collide. EU MDR requires clinical evidence for medical devices, which often involves processing patient data. Collecting, storing, and analysing clinical data across US and EU jurisdictions triggers HIPAA obligations (for US-sourced data) and GDPR obligations (for EU-sourced data). The lawful bases for processing differ, the consent requirements differ, and the cross-border transfer mechanisms differ. Organisations frequently underestimate the compliance burden of clinical evidence programmes that span both jurisdictions.

Supplier and third-party management differs. HIPAA requires Business Associate Agreements (BAAs) with any entity that handles PHI on behalf of a covered entity. EU MDR requires manufacturers to maintain oversight of their supply chain and ensure suppliers operate within the quality management system. These are different obligations with different documentation requirements, but for a connected medical device with cloud-based data processing, both apply to the same suppliers. Organisations that manage HIPAA BAAs and EU MDR supplier obligations in separate silos often find gaps in coverage.

Incident response and reporting timelines conflict. A security incident involving a connected medical device may trigger reporting obligations under both HIPAA and EU MDR simultaneously. The timelines differ (60 days vs. 2-15 days), the information required differs, and the recipients differ. Without a unified incident response framework that accounts for both sets of obligations, organisations risk missing one or both reporting deadlines.

Software lifecycle management. For SaMD products, HIPAA applies to the data the software processes, while EU MDR applies to the software itself as a medical device. Software updates, algorithm changes, and new feature deployments must be evaluated under EU MDR’s change management requirements (which may trigger a new conformity assessment) while simultaneously maintaining HIPAA compliance for data handling. These two sets of change management obligations are rarely integrated.

Building a unified compliance approach

Organisations subject to both HIPAA and EU MDR benefit from a compliance architecture that maps obligations from both frameworks onto their operations simultaneously rather than treating them as separate compliance programmes.

This requires understanding each obligation individually — its trigger conditions, its evidence requirements, and its risk profile — and then mapping where obligations from different frameworks apply to the same processes, systems, or products. AuditDSS covers both HIPAA and EU MDR, applying 4-axis risk scoring that evaluates obligations across multiple dimensions. This approach allows compliance teams to see where frameworks overlap, where they impose conflicting requirements, and where gaps exist that neither framework addresses alone.

The goal is not to merge two compliance programmes into one. The frameworks are too different for that. The goal is to have a single view of all obligations that apply to your operations, regardless of which framework they originate from, so that compliance decisions are made with full visibility of the regulatory landscape.

Cross-border healthcare compliance is inherently complex. But the complexity becomes manageable when obligations are understood at a granular level, mapped to specific operational processes, and monitored systematically. The organisations that struggle are the ones that treat HIPAA and EU MDR as separate problems to be solved by separate teams. The organisations that succeed are the ones that see them as two perspectives on the same operations — and build their compliance architecture accordingly.